|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Anemia, megaloblastic |
|
Carcinoma, colorectal, adjunct |
|
Osteosarcoma |
|
Toxicity, methotrexate |
| |
|
|
SIDE EFFECTS:
|
|
Allergic reaction |
|
seizures |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
|
|
ADULT DOSE:
|
|
Antidote (to folic acid antagonists)-
To methotrexate-
Oral, 10 mg (base) per square meter of body surface area every six hours until methotrexate blood concentrations fall to less than 5 ´ 10 M.
To pyrimethamine or trimethoprim-
Prevention-Oral, 400 mcg (0.4 mg) to 5 mg (base) with each dose of the folic acid antagonist.
Treatment-Oral, 5 to 15 mg (base) per day.
Megaloblastic anemia, secondary to folate deficiency-
Oral, up to 1 mg (base) per day.
Note: Doses higher than 25 mg should be given parenterally because oral absorption is saturable at doses above 25 mg . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Antidote (to folic acid antagonists)-
To methotrexate-
Oral, 10 mg (base) per square meter of body surface area every six hours until methotrexate blood concentrations fall to less than 5 ´ 10 M.
To pyrimethamine or trimethoprim-
Prevention-Oral, 400 mcg (0.4 mg) to 5 mg (base) with each dose of the folic acid antagonist.
Treatment-Oral, 5 to 15 mg (base) per day.
Megaloblastic anemia, secondary to folate deficiency-
Oral, up to 1 mg (base) per day.
Note: Doses higher than 25 mg should be given parenterally because oral absorption is saturable at doses above 25 mg . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|